Skip to content

Clinical study on early diagnosis of biliary tract malignant tumor by comprehensive endoscopic technique

Clinical study on early diagnosis of biliary tract malignant tumor by comprehensive endoscopic technique

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100041698
Enrollment
Unknown
Registered
2021-01-01
Start date
2021-12-01
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma

Interventions

Gold Standard:Histological biopsy
Index test:Biochemical&#32
and&#32
imaging&#32
examinations&#32
after&#32
ERCP

Sponsors

Dongfang Hospital Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) The included patients include patients with unexplained bile duct stenosis and suspected pancreaticobiliary carcinoma who are planned for ERCP.Patients, regardless of whether they have done or have not done cholangiopancreatography before. (2) During ERCP operation, preoperative images, clinical data suggest suspicious pancreaticobiliary duct tumor or pancreaticobiliary duct disease unknown quality. (3) Volunteer to participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) People with poor communication skills and compliance or mental illness; (2) Intestinal stenosis, obstruction and severe varicose veins caused by ulcers, tumors or other reasons, endoscopic failure can enter the descending part of the duodenum; (3) The general condition of the patient is extremely poor and cannot tolerate endoscopy, including heart, brain, liver, kidney, lung severe function failure, etc. (4) Patients with severe blood coagulation disorders and bleeding disorders. (5) A history of allergy to related drugs, such as anesthetics, fluorescein sodium, etc. (6) Pregnant or planning to become pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Pathological results;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactLinheng Wang

Dongfang Hospital Beijing University of Chinese Medicine

wanglinheng@sina.com+86 13370129665

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026